Forteo no better than oral risedronate for back pain from vertebral fractures
21:35 EDT 8 Aug 2012 | SCRIP
Eli Lilly reported that its bone-building anabolic drug Forteo (teriparatide [rDNA origin] injection) was no more effective than oral risedronate (Warner Chilcott's Actonel) in a Phase III clinical trial evaluating the relief of back pain.....
Original Article: Forteo no better than oral risedronate for back pain from vertebral fractures
More From BioPortfolio on "Forteo no better than oral risedronate for back pain from vertebral fractures"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
